These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23754771)

  • 41. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality check of spontaneous adverse drug reaction reporting forms of different countries.
    Bandekar MS; Anwikar SR; Kshirsagar NA
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1181-5. PubMed ID: 20845409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The AMSP drug safety program: methods and global results.
    Grohmann R; Engel RR; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S4-11. PubMed ID: 15052509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse drug reaction reporting by nurses: analysis of Italian pharmacovigilance database.
    Conforti A; Opri S; D'Incau P; Sottosanti L; Moretti U; Ferrazin F; Leone R
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):597-602. PubMed ID: 22337264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe and uncommon involuntary movement disorders due to psychotropic drugs.
    Stübner S; Rustenbeck E; Grohmann R; Wagner G; Engel R; Neundörfer G; Möller HJ; Hippius H; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S54-64. PubMed ID: 15052515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Research on early warning signals of adverse drug reactions to parenterally administered xiyanping based on spontaneous reporting system (SRS) data].
    Wang ZF; Xiang YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3008-12. PubMed ID: 24471321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study.
    Grohmann R; Engel RR; Geissler KH; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S27-38. PubMed ID: 15052512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Core Concepts Involving Adverse Psychotropic Drug Effects: Assessment, Implications, and Management.
    Goldberg JF; Ernst CL
    Psychiatr Clin North Am; 2016 Sep; 39(3):375-89. PubMed ID: 27514295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Loughlin AM; Marchant CD; Adams W; Barnett E; Baxter R; Black S; Casey C; Dekker C; Edwards KM; Klein J; Klein NP; LaRussa P; Sparks R; Jakob K
    Vaccine; 2012 Nov; 30(50):7253-9. PubMed ID: 23063829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can reporting of adverse drug reactions create safer systems while improving health data?
    Hohl C; Lexchin JR; Balka E
    CMAJ; 2015 Aug; 187(11):789-790. PubMed ID: 25941261
    [No Abstract]   [Full Text] [Related]  

  • 53. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal.
    Crépin S; Villeneuve C; Merle L
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):719-24. PubMed ID: 26887649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population.
    Bygdell M; Brunlöf G; Wallerstedt SM; Kindblom JM
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):79-86. PubMed ID: 22076661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug reactions: keeping up to date.
    Aronson JK; Derry S; Loke YK
    Fundam Clin Pharmacol; 2002 Feb; 16(1):49-56. PubMed ID: 11903512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic adverse effects: another example of undernotification.
    Prescrire Int; 2003 Feb; 12(63):19. PubMed ID: 12602390
    [No Abstract]   [Full Text] [Related]  

  • 57. Assessing Adverse Drug Reactions from Psychotropic Medications Reported to the U.S. Food and Drug Administration in Older Adults.
    Gray MP; Dziuba G; Quach K; Wong A; Smithburger PL; Seybert AL; Kane-Gill SL
    Am J Geriatr Psychiatry; 2019 Feb; 27(2):181-185. PubMed ID: 30503701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychotropic drug-related rhabdomyolysis.
    Jermain DM; Crismon ML
    Ann Pharmacother; 1992; 26(7-8):948-54. PubMed ID: 1504409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case reports of suspected adverse drug reactions: case reports were dismissed too quickly.
    Vandenbroucke JP
    BMJ; 2006 Feb; 332(7539):488. PubMed ID: 16497772
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug-induced hperpigemntation: a systematic review.
    Krause W
    J Dtsch Dermatol Ges; 2013 Jul; 11(7):644-51. PubMed ID: 23650908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.